Geneos Wealth Management’s DexCom DXCM Stock Holding History

Geneos Wealth Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.06M	Buy	16,954 +5	+0%	+$348	0.02%	493
2025 Q4	$1.12M	Buy	16,949 +11,080	+189%	+$716K	0.03%	474
2025 Q3	$395K	Buy	5,869 +115	+2%	+$9.1K	0.01%	721
2025 Q2	$502K	Sell	5,754 -6,936	-55%	-$544K	0.01%	706
2025 Q1	$867K	Buy	12,690 +6,496	+105%	+$530K	0.01%	711
2024 Q4	$482K	Sell	6,194 -165	-3%	-$12.2K	0.02%	603
2024 Q3	$426K	Buy	6,359 +421	+7%	+$34.6K	0.02%	597
2024 Q2	$673K	Sell	5,938 -88	-1%	-$11.1K	0.03%	427
2024 Q1	$836K	Sell	6,026 -33	-0.5%	-$4.15K	0.04%	384
2023 Q4	$752K	Sell	6,059 -359	-6%	-$36.7K	0.04%	383
2023 Q3	$599K	Sell	6,418 -960	-13%	-$108K	0.03%	427
2023 Q2	$948K	Buy	7,378 +1,233	+20%	+$149K	0.05%	324
2023 Q1	$714K	Sell	6,145 -1,334	-18%	-$149K	0.04%	368
2022 Q4	$847K	Sell	7,479 -657	-8%	-$72.1K	0.05%	303
2022 Q3	$655K	Buy	8,136 +207	+3%	+$17.5K	0.05%	333
2022 Q2	$615K	Sell	7,929 -191	-2%	-$17.4K	0.03%	445
2022 Q1	$1.04M	Sell	8,120 -2,720	-25%	-$298K	0.04%	344
2021 Q4	$1.46M	Sell	10,840 -104	-1%	-$14.9K	0.06%	307
2021 Q3	$1.5M	Buy	10,944 +368	+3%	+$46.4K	0.06%	296
2021 Q2	$1.14M	Buy	10,576 +5,632	+114%	+$541K	0.04%	330
2021 Q1	$477K	Sell	4,944 -120	-2%	-$11.3K	0.01%	648
2020 Q4	$417K	Buy	5,064 +440	+10%	+$39.3K	0.02%	586
2020 Q3	$465K	Sell	4,624 -260	-5%	-$27.2K	0.02%	450
2020 Q2	$467K	Sell	4,884 -160	-3%	-$14.3K	0.03%	426
2020 Q1	$331K	Buy	5,044 +360	+8%	+$22.4K	0.02%	470
2019 Q4	$255K	Sell	4,684 -400	-8%	-$19K	0.01%	604
2019 Q3	$188K	Hold	5,084	–	–	0.01%	681
2019 Q2	$190K	Hold	5,084	–	–	0.01%	686
2019 Q1	$151K	Sell	5,084 -64	-1%	-$2.25K	0.01%	733
2018 Q4	$152K	Buy	5,148 +400	+8%	+$12.7K	0.01%	686
2018 Q3	$169K	Sell	4,748 -648	-12%	-$20.1K	0.01%	701
2018 Q2	$128K	Sell	5,396 -2,000	-27%	-$42.4K	0.01%	706
2018 Q1	$137K	Buy	7,396 +1,100	+17%	+$16.3K	0.01%	648
2017 Q4	$90K	Hold	6,296	–	–	0.01%	779
2017 Q3	$77K	Hold	6,296	–	–	0.01%	788
2017 Q2	$115K	Sell	6,296 -44	-0.7%	-$813	0.01%	644
2017 Q1	$134K	Buy	6,340 +6,092	+2,456%	+$119K	0.01%	578
2016 Q4	$3K	Buy	248 +96	+63%	+$1.7K	﹤0.01%	1753
2016 Q3	$3K	Buy	+152	New	+$3.38K	﹤0.01%	1685

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geneos Wealth Management's DXCM Position: Q1 2026 in Review

Geneos Wealth Management increased its DexCom (DXCM) stake by 0.03% in Q1 2026, buying an estimated $348 and bringing the position to 16,954 shares worth $1.06M. The position accounts for 0.02% of the portfolio, ranked #493.

Geneos Wealth Management first reported a position in DXCM in Q3 2016 and has held it in 39 quarters since. The position peaked at $1.5M in Q3 2021. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

Geneos Wealth Management held 16,954 shares of DexCom worth $1.06M as of Q1 2026.
Geneos Wealth Management bought 5 DexCom shares in Q1 2026, an estimated $348.
DexCom made up 0.02% of Geneos Wealth Management's portfolio in Q1 2026, its #493 holding.
Geneos Wealth Management first reported a position in DexCom in Q3 2016 and has held it in 39 quarters since.
Geneos Wealth Management's DexCom position peaked at $1.5M in Q3 2021.
956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.